Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines

Study Identifier
191622-098
CT.gov Identifier
NCT01189747
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Facial Aesthetics - Toxins
    • Study Drug
  • onabotulinumtoxinA
  • normal saline
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Moderate to severe Crow's Feet Lines * Have adequate vision without the use of eyeglasses to assess facial wrinkles in a mirror (contact lenses OK)
    Exclusion Criteria:
    * Current or previous botulinum toxin treatment of any serotype * Facial laser or light treatment, microdermabrasion or superficial peels within 3 months * Oral retinoid therapy within 1 year * Prior facial cosmetic surgery (eg, periorbital surgery, facial lift, brow lift, eye lift, or eyebrow surgery) * Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis

    Protocol Summary

    This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthal Rhytides).

    Study Locations

    Location
    Status
    Location
    Newport Beach, California, United States
    Status
    Not applicable
    Location
    Aalst, Belgium
    Status
    Not applicable
    Location
    Vancouver, British Columbia, Canada
    Status
    Not applicable
    Location
    Sutton Coldfield, England, United Kingdom
    Status
    Not applicable